Piceatannol improved cerebral blood flow and attenuated JNK3 and mitochondrial apoptotic pathway in a global ischemic model to produce neuroprotection

• Published in: Naunyn-Schmiedeberg's archives of pharmacology Vol. 397; no. 1; pp. 479 - 496
• Main Authors: Rajan, Ravi Kumar, Kumar, Ram Pravin, Ramanathan, M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 2024; Springer Nature B.V
• Subjects: Amino acids; Apoptosis; Biomedical and Life Sciences; Biomedicine; Blood flow; c-Jun protein; Caspase; Cerebral blood flow; Gene expression; Inflammation; Ischemia; JNK protein; JNK3 protein; Kinases; Mitochondria; Neuroprotection; Neurosciences; Nitric-oxide synthase; Pharmacology/Toxicology; Phosphorylation; Piceatannol; Recovery of function; Reperfusion; Resveratrol; Signal transduction; Transcription factors; PCT; SP6; Cerebral ischemia; c-Jun N-terminal kinase 3; Global ischemia; CBF
• ISSN: 0028-1298; 1432-1912
• DOI: 10.1007/s00210-023-02616-0

Cerebral ischemia is one of the leading causes of death and disability worldwide. The only FDA-approved treatment is recanalization with systemic tissue plasminogen activators like alteplase, although reperfusion caused by recanalization can result in neuroinflammation, which can cause brain cell apoptosis. Therefore, after an ischemic/reperfusion injury, interventions are needed to minimize the neuroinflammatory cascade. In the present study, piceatannol (PCT) was studied for its neuroprotective efficacy in a rat model of global ischemic injury by attenuating c-Jun N-terminal kinase 3 (JNK3) downstream signaling. PCT is a resveratrol analog and a polyphenolic stilbenoid naturally occurring in passion fruit and grapes. The neuroprotective efficacy of PCT (1, 5, 10 mg/kg) in ischemic conditions was assessed through pre- and post-treatment. Cerebral blood flow (CBF) and tests for functional recovery were assessed. Protein and gene expression were done for JNK3 and other inflammatory markers. A docking study was performed to identify the amino acid interaction. The results showed that PCT improved motor and memory function as measured by a functional recovery test believed to be due to an increase in cerebral blood flow. Also, the caspase signaling which promotes apoptosis was found to be down-regulated; however, nitric oxide synthase expression was up-regulated, which could explain the enhanced cerebral blood flow (CBF). According to our findings, PCT impeded c-Jun N-terminal kinase 3 (JNK3) signaling by suppressing phosphorylation and disrupting the mitochondrial apoptotic pathway, which resulted in the neuroprotective effect. Molecular docking analysis was performed to investigate the atomic-level interaction of JNK3 and PCT, which reveals that Met149, Leu206, and Lys93 amino acid residues are critical for the interaction of PCT and JNK3. According to our current research, JNK3 downstream signaling and the mitochondrial apoptosis pathway are both inhibited by PCT, which results in neuroprotection under conditions of global brain ischemia.
Graphical abstract
Piceatannol attenuated JNK3 phosphorylation during the ischemic condition and prevented neuronal apoptosis